Conference call - Update on Clinical Strategy

Conference call - Update on Clinical Strategy

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

Celyad to Present at the Cantor Fitzgerald Global Healthcare Conference

Celyad to Present at the Cantor Fitzgerald Global Healthcare Conference

Conference call Celyad first half 2017

Conference call Celyad first half 2017

Celyad Reports First Half 2017 Financial Results and Operational Progress

Celyad Reports First Half 2017 Financial Results and Operational Progress

Celyad announces new agreements with Celdara Medical and Dartmouth College

Celyad announces new agreements with Celdara Medical and Dartmouth College

Celyad announces initiation of the SHRINK trial

Celyad announces initiation of the SHRINK trial

Celyad publishes additional pre-clinical data in support of THINK trial

Celyad publishes additional pre-clinical data in support of THINK trial

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

Celyad obtains additional US patent for cancer treatment based on TCR-deficient allogeneic CAR-T cells

Celyad obtains additional US patent for cancer treatment based on TCR-deficient allogeneic CAR-T cells

Celyad Announces First Quarter 2017 Business Update

Celyad Announces First Quarter 2017 Business Update

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure®

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure®